Altido Therapeutics Raises $12.5M to Advance CAR-T Therapy for Glioblastoma
核心洞察
Altido Therapeutics (搜索), led by gene therapy veteran Nick Leschly, has closed a $12.5 million seed round to commercialize a CAR-T cell therapy (搜索) for glioblastoma (搜索) developed at Massachusetts General Hospital.
Early trial data showed all three initial patients experienced significant tumor shrinkage, with one patient remaining alive and well more than 2.5 years after treatment.
The company is now pursuing a $75 million Series A funding round to advance the therapy for glioblastoma (搜索), a nearly always fatal brain tumor.
Nick Leschly, the CEO who became synonymous with the curative promise and complicated reality of gene therapy, has launched Altido Therapeutics (搜索) to commercialize a CAR-T cell therapy (搜索) for glioblastoma (搜索), one of the most aggressive and deadly brain cancers. The startup recently closed a $12.5 million seed round led by ARCH Venture (搜索) and is actively pursuing a $75 million Series A funding round.
Promising Early Clinical Results
The CAR-T therapy being developed by Altido was originally created at Massachusetts General Hospital (MGH) and has shown encouraging early results in treating glioblastoma (搜索), a nearly always fatal brain tumor. Data from the initial trial demonstrate that all three of the first patients treated experienced immediate and significant tumor shrinkage.
While two of these patients eventually relapsed and died, one patient remains alive and well today, more than 2.5 years after receiving the treatment. This extended survival represents a notable achievement given glioblastoma (搜索)'s typically grim prognosis.
Addressing an Urgent Medical Need
The early data have generated considerable excitement within the medical community, particularly given the devastating nature of glioblastoma (搜索) and the limited therapeutic options currently available. The disease's nearly universal fatality rate underscores the critical need for innovative treatment approaches like the CAR-T therapy Altido is developing.
Funding and Development Strategy
With the completion of its seed funding round, Altido is now positioned to advance the MGH-developed CAR-T therapy through the regulatory and development process. The company's pursuit of a substantial Series A round reflects the significant investment required to bring complex cell therapies from early-stage research to commercial availability.
The involvement of ARCH Venture (搜索), a prominent venture capital firm with extensive experience in biotechnology investments, signals confidence in both the therapeutic approach and the leadership team's ability to execute on the commercialization strategy.